The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging markets with no patents.

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.